Text Size

The Influence of Cessation of Pomegranate Juice Intake on Inflammation and Oxidative Stress Markers and Glucose Control in Diabetic and Non Diabetic Chronic Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
Western Galilee Hospital-Nahariya
ClinicalTrials.gov Identifier:
NCT01033435
First received: December 15, 2009
Last updated: August 16, 2011
Last verified: August 2011
History of Changes
  Purpose

The current study will investigate chronic hemodialysis patients who were treated in our unit with pomegranate juice intake for 1 year - compared to a control group.

Markers will be taken 3 months after cessation of pomegranate juice intake, for inflammation and oxidative stress and Hb A1c.


Condition Intervention
Inflammation
Oxidative Stress
 Other: No intervention

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Further study details as provided by Western Galilee Hospital-Nahariya:

Enrollment: 49
Study Start Date: December 2009
Study Completion Date: August 2011
Groups/Cohorts Assigned Interventions
chronic Hemodialysis patients, treated in our unit. Other: No intervention
chronic Hemodialysis patients , No intervention
chronic Hemodialysis patients, treated in our unit.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

chronic Hemodialysis patients, treated in our unit.

Criteria

Inclusion Criteria:

  • Chronic Hemodialysis patients three months after termination of study which is currently carried out at our unit; which compared patients taking pomegranate juice three times a week for 1 year to a group that received placebo juice.

Exclusion Criteria:

  • Patients who do not currently participate in above mentioned trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01033435

Locations
Israel
Western Galilee Hospital
Nahariya, Western Galilee, Israel, 25100
Sponsors and Collaborators
Western Galilee Hospital-Nahariya
  More Information

No publications provided

Responsible Party: Dr. Ronit Geron, Deputy Head of Department, Nephrology and Hypertension Department, Western Galilee Hospital, Nahariya
ClinicalTrials.gov Identifier: NCT01033435     History of Changes
Other Study ID Numbers: Gron09
Study First Received: December 15, 2009
Last Updated: August 16, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by Western Galilee Hospital-Nahariya:
Inflammation
Oxidative stress
HbA1c
Hemodialysis

Additional relevant MeSH terms:
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on May 22, 2013